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ABSTRACT

Brain cancer treatments have long been restricted by the blood-brain barrier (BBB).
Semi-permeable in the most selective way, this barrier may be crossed by one of three methods:
membrane integrity disruption, passive transport, or active transport. The third option offers the
opportunity for many medically relevant cargoes, such as proteins and nucleic acids, to be
shuttled into the brain. The concept of a therapeutic “Trojan horse” builds on this capability by
employing engineered nanovesicles—in this work, engineered exosomes—whose surfaces are
studded with ligands functioning as the keys to crossing the BBB. Exosomes are a powerful
methodology for this approach because they have evolved to be the body’s natural messengers,
carrying and delivering bioactive cargo from one cell to another. This work was built on years of
research in the field of engineering the exosome’s natural capacities—cargo loading, in vivo
survivability, targeting, cellular uptake—in order to execute specific therapeutic functions.
Namely, the engineerability of three proteins—rabies virus glycoprotein (RVG), transferrin (TN),
and neural cell adhesion molecule (NCAM)—were investigated because they have individually
been reported to mediate either active transport across the BBB or targeting of neurons. When
put together on an engineered exosome’s surface, these two functionalities are vital pieces of the
brain cancer treatment development puzzle. Herein, the tools of confocal microscopy, liquid
chromatography-mass spectroscopy (LC-MS), and next-generation sequencing (NGS) provided
insight into the efficacy of engineering exosomes with two different combinations of these
proteins of interest. An aspect of preclinical safety was evaluated by further NGS analysis, and
an initial uptake assay was performed. Notably, as a proof of concept, the sample sizes were low;
therefore, conclusions should be considered as flexible to the findings of future research.
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1.

INTRODUCTION
1.1.

Background
Gaining access to the brain has always been a challenge for therapeutics [1,2,3,4].
Evolved to be the most selective barrier in the human body, the blood-brain
barrier (BBB) presents the medical field the double-edged sword of protecting the
brain from damaging agents while also refusing entry to aspiring treatments.
Consequently, the journey for a therapeutic, from administration to action, has
been obstructed by four primary challenges: (i) surviving in vivo, (ii) crossing the
BBB, (iii) targeting diseased brain tissue, and (iv) being taken up by target cells
[2,3,4]. A fifth challenge exists in designing a therapeutic technique around these
hurdles that operates with low off-target immunogenicity [3].
Were this path into the brain to be navigable by a novel treatment method, a
massive door would be opened, allowing research into understanding and treating
neurological disorders, be they behavioral, physiological, cancerous, or otherwise
[1]. At the same time, a problem of this complexity—although its answer carries
such potential—cannot be tackled all at once, but rather in methodical steps.
Eventually, as research continues to discover different pieces of the puzzle, the
medical community may learn how to safely, reliably, and effectively open this
door.

1.2.

State of the Field and Opportunities for Growth
Many efforts have been made towards surpassing the BBB, such as creating
transient holes in the brain’s protective vasculature by chemical or radiological
disruption, modifying drugs to encourage passive BBB permeability, and utilizing
the BBB’s inherent active transport systems as targets for therapeutic “Trojan
horses” [4]. The first approach is extremely dangerous because the entire
protection of the BBB must be compromised. The second approach, in contrast, is
non-invasive, but only small molecules are eligible, thereby limiting the
indications that may be treated. The third approach, also non-invasive, has the
capacity to shuttle a greater variety of bioactive cargo across the BBB, including
proteins and nucleic acids. These cargoes have demonstrated the potential to
affect some of today’s most challenging illnesses, from metabolic ailments to
neurological disorders to cancer [1]. Additionally, when the Trojan horse consists
of a nanovesicle with receptors that will provoke its transport into the brain, the
bioactive cargo can be protected until it reaches its target, thus limiting both
degradation and off-target effects [3]. Importantly, nanovesicles studded with
RVG have been shown to be targetable to neurons [5,6,7]. Furthermore,
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transcytosis—an active transport process mediated by ligands such as TN and
NCAM—has been identified as the method by which extracellular vesicles, like
exosomes, are able to cross the BBB [8]. This knowledge allows researchers to
focus engineering efforts on improving the active transport and targetability of
exosomes to develop brain-targeting therapeutics.
Accordingly, nanovesicles are being looked into as a valuable frontier leading into
treating BBB-bounded disorders such as brain cancer [3]. Diving into this
methodology, from liposomes and synthetic polymers to gold nanoparticles and
exosomes, the differences between technologies becomes apparent. The three
formerly mentioned are synthetic in nature and, therefore, are more homogeneous
than the cell-derived exosome. They have demonstrated medical relevance by
being readily engineerable drug delivering vehicles capable of carrying drugs in a
protected manner and of improved cellular uptake [9]. However, they have their
downsides, namely: low in vivo survivability, organ toxicity, difficulty delivering
certain cargoes, and a limited ability to predict how the synthetic nanovesicle will
interact with the body [9,10,11]
On the other hand, exosomes naturally possess many of the capabilities observed
in their synthetic counterparts, and more [1,2,9,12,13]. The exosome is by its very
nature a biocompatible technology [1]. Pair these innate characteristics with the
ability to engineer exosomes to express constructs of interest on their
membrane—inwardly or outwardly facing—and to load diverse therapeutic cargo,
and the exosome becomes a powerful, biocompatible technology for delivering
medicine in a targeted fashion [13,14].
Before engineering exosomes for therapeutic purposes, there is value in
understanding their biology. Exosomes are the carriers the human body uses to
deliver bioactive “messages”—from instructions encoded in various RNA types,
to signaling proteins, and more—from one cell to another. In this role as
biological communicators, exosomes are naturally capable of safely carrying a
variety of medically relevant cargo in a targeted way to then be taken up by
recipient cells. Thus, the question becomes: How can the natural capabilities of
exosomes be engineered to perform specific therapeutic functions?
1.3.

Research Objective
This question has been studied from numerous angles, and another step towards
elaborating on the answer is the goal of this work. With hurdles as complex as
those faced while trying to treat brain cancer, the path for developing a novel
therapeutic capable of making a targeted impact on the brain must be piecewise.
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Solutions to each challenge must be validated individually before being put
together, otherwise there exist too many variables to evaluate at once.
Herein, a series of research projects has been built upon. The larger project has
focused on engineering exosomes to provide them with enhanced capabilities for
the targeted delivery of therapeutics. First, an engineering strategy was designed
to be capable of integrating fusion proteins into the exosome’s surface, luminally
or externally facing [14]. Next, exosomes were shown to be able to be imaged in
vitro via genetic labeling and to be loaded with therapeutics [13,15]. The
engineering of these protein constructs into the surfaces of exosomes was
optimized by a VSVG scaffold, and the engineered exosomes were shown to be
able to be taken up by target cells in vitro [12,13,16].
The next step involved directing these technologies towards a pressing and
perplexing medical challenge: delivering therapeutics across the BBB.
Subsequently, proteins of interest (POI) were identified that may confer medically
relevant characteristics to engineered exosomes [5,6,7,17,18,19,20]. These
characteristics correspond to the four primary challenges of survival, BBB
crossing, targeting, and therapeutic cargo delivery. The present work focuses on
the second and third hurdles by studying the engineerability of three proteins:
rabies virus glycoprotein (RVG), transferrin (TN), and neural cell adhesion
molecule (NCAM).

2.

MATERIALS AND METHODS [12,14,21,22,23]
2.1.

Design and Construction of Protein Constructs
This project revolved around three protein constructs: rabies virus glycoprotein
(RVG), transferrin (TN), and neural cell adhesion molecule (NCAM). RVG has
been indicated as being able to selectively target neurons, while TN and NCAM
have been indicated as surface proteins capable of shuttling biological
components across the blood-brain barrier (BBB) [5,6,7,17,18,19,20]. The
plasmid DNA constructs for each of these three functional surface proteins were
designed by David Diebold and Kyle Asano and constructed by GenScript (NJ,
USA). Key features designed into the constructs included truncated VSVG
(tVSVG) and a reporter gene. VSVG, or vesicular stomatitis virus G protein, has
been shown in prior work to encourage the integration of a transfected construct
into the membrane of an engineered exosome [12,24,25,26,27]. The truncated
VSVG maintains the most relevant component of the protein, while also reducing
its size for the sake of being more readily produced by parent cells. GFP or
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RFP—green and red fluorescent protein, respectively—were utilized as reporters
in order to visualize, track, and quantify the progress of the biomolecular
engineering processes discussed herein. Also of note, two additional constructs
were used as exosome markers. One of these constructs was CD63 and the other
was XPackTM (System Biosciences; CA, USA), and both constructs included an
RFP reporter. Both of these constructs were used in colocalization experiments to
evaluate the biodistribution of the RVG, TN, and NCAM constructs because
CD63 and XPackTM have been cited as valid exosome markers [28,29,30].

Fig. 1: Construct design and engineered exosome schematic. (a) Schematic understanding of
the primary three constructs studied herein, namely transferrin (TN), neural cellular adhesion
molecule (NCAM), and rabies virus glycoprotein (RVG). Notably, only the single
RVG-containing construct was studied. (b) This figure illustrates the components of an
engineered exosome designed to deliver a therapeutic cargo to a neuron affected by brain cancer.
A BBB-crossing function would be mediated by either TN or NCAM, and a neuron-targeting
function would be mediated by RVG. Groundwork for being able to effectively load exosomes
with therapeutic cargoes has been established [1,13,22,23].
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2.2.

Cell Culture
All exosomes were derived from 293T cells acquired from Alstem in Richmond,
CA, USA. These cells were selected because they are a healthy human cell line,
thereby allowing for more medically relevant conclusions to be drawn from the
data collected. The cells were maintained and cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) (Gibco; MA, USA) supplemented with 10% fetal
bovine serum (FBS) (GE Healthcare Life Sciences; WA, USA) and 1% penicillin
streptomycin (Pen Strep) (Gibco; MA, USA). Cell passaging was performed twice
a week, allowing for the cells to reach a confluence of 70-80% before passaging.
The adherent cells were prepared for passage with a phosphate-buffered saline
(PBS) (Bio-Rad Laboratories; CA, USA) rinse followed by a brief incubation
with 0.25% trypsin-ethylenediaminetetraacetic acid (Trypsin-EDTA) (Gibco; MA,
USA) to release the cells from their plates. If the cells were to be transfected, they
would be seeded on 4-chamber 35mm imaging plates with a 20mm glass bottom
well (Cellvis; CA, USA). If they were to be used to harvest exosomes, they would
be seeded on a 145/200mm cell culture dish (Cellvis; CA, USA). Otherwise, the
cells were seeded on 100x20mm cell culture dishes (Greiner Bio-One; NC, USA).
Between passages and experiments, cells were kept in an incubator maintained at
37oC and 5% CO2.

2.3.

Transient Transfection
The engineering process for decorating exosomal surfaces with fusion proteins
involved introducing the DNA for the constructs we wanted to be expressed via a
transient transfection procedure facilitated by polyethylenimine (PEI).
Specifically, once the cells had achieved ~70% confluence, they were transfected
with a solution containing plasmid DNA (0.5 μg/chamber), PEI transfection
reagent (2.5 μL/chamber), and Opti-MEMTM (50 μL/chamber) (Gibco; MA,
USA). These concentrations were scaled linearly if the cells to be transfected
were grown in plates of different sizes. This solution sat for 20 minutes prior to
transfection to allow for PEI to form around the plasmid DNA, thus facilitating
transient transfection.

2.4.

Live Cell and Exosome Microscopy
Following transient transfection with PEI, the cells were allowed to ingest and
process the plasmid DNA for 24H before imaging. Notably, the timing for both
live cell and exosome imaging was important because the fluorescent signal
accompanying properly expressed constructs changes over time. For these
images, a confocal microscope (Leica Microsystems; Wetzlar, Germany) was
employed. This particular microscope has many functions–from Z-focusing to
overlapping to contrast and fluorescence imaging with single-cell resolution–that
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were enabled by Leica Application Suite X software. Live cell imaging was
performed at 24H, 48H, and 72H following transfection. Exosome imaging was
performed by allowing a small drop of isolated exosomes to settle onto a fresh
4-chamber imaging plate before visualization. Depending on the transfected
construct’s fluorophore, and on whether or not the cells had been stained with
Hoechst dye, GFP, RFP, and DAPI settings were imaged with a 40X
magnification oil immersion lens. Fluorescence crosstalk in experiments with
multiple fluorescent signals was mitigated with the Leica software, and contrast
images were overlaid with fluorescence images for discerning fluorescent
biodistribution using the same software. In the case of imaging exosomes, the
exposure was doped to be twice as strong in order to pick up the fluorescent
signals from this small species.
2.5.

Hoechst Staining
The nuclei of live cells were stained with Hoechst dye (Thermo Fisher Scientific;
MA, USA) at the 72H mark following transfection to discern whether or not the
cells were still viable. This staining procedure involved removing the cell culture
medium, washing the cells with PBS, briefly incubating the cells with a 1:1000
Hoecsht dye:PBS dilution, then rinsing again with PBS before imaging the cells
in PBS.

2.6.

Exosome Preparation and Isolation
Preparation for exosome harvest from 293T cells began with seeding the cells on
145x20mm cell culture dishes (Cellvis; CA, USA) with the same DMEM + 10%
FBS + 1% Pen Strep media. If the exosomes were to be engineered, at ~70%
confluency the cells were transfected using the same protocol described above,
but scaled to this larger plate (20 μg plasmid DNA, 100 μL PEI, 1 mL
Opti-MEMTM per plate). For control exosomes, the transfection step was omitted.
The next day, the media for all samples was replaced with UltracultureTM
(Sartorius Stedim Biotech; MD, USA) + 1% Pen-Strep/Glutamine (Gibco; MA,
USA). The transfected cells were allowed to grow in this serum-free medium for
48-72H before their conditioned media was collected. This collected media was
then centrifuged at 1500g for 10 minutes in a Sorvall ST 16R centrifuge (Thermo
Fisher Scientific; MA, USA) before being filtered through a 0.2 μm
polyethersulfone filter (VWR International; PA, USA). This filter was small
enough to allow for exosomes to pass through, but not cellular debris and
unwanted extracellular components. To this filtered conditioned media, ExoQuick
TC (Teknova; CA, USA) was added at a concentration of 5 mL per 20 mL filtered
conditioned media and allowed to incubate in a 4oC fridge overnight. The
following day, this solution was centrifuged at 3000g for 1.5H using the same
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Sorvall centrifuge. The final isolated exosome product appeared as a small pellet
at the bottom of the tube. Finally, the supernatant was decanted, the tube was
placed upside down on paper towels for 10 min, and the exosome pellet was
resuspended in 100-200 μL PBS. An initial exosome concentration was roughly
determined via the protein concentration feature on a NanoDropTM Lite
spectrophotometer (Thermo Fisher Scientific; MA, USA) before the isolated
exosomes were stored in a -20oC fridge while they awaited further
characterization.
2.7.

Flow Cytometry
The BD Accuri TM C6 Plus Flow Cytometer (BD Biosciences; CA, USA) was
utilized to gain insight into the transfection efficiency of the 293T cells. The
machine’s operation was guided by its provided manual, as well as by Dr.
Unyoung (Ashley) Kim and Steven Krickovich from BD Biosciences’ Technical
Service team. Generally, the preparation for analyzing samples involved ensuring
proper start-up, running a SIP clean with BD TM FACSClean solution (BD
Biosciences; CA, USA) and filtered DI water, performing a backflush, validating
the machine’s efficacy with a quality control that relied on BDTM CS&T RUO
Beads (BD Biosciences; CA, USA), and straining each sample with a 40 μm
CorningTM FalconTM cell strainer (Thermo Fisher Scientific; MA, USA) to prevent
clogging and inaccurate results. Additionally, SIP cleans and backflushes were
performed between each sample. Before shutting the machine down, another SIP
clean was performed. The results from these flow cytometer experiments were
collected and analyzed by the software that came with this flow cytometer.
Results were formatted using Microsoft Excel (Microsoft; WA, USA).

2.8.

Exosomal Next-Generation Sequencing Analysis
To assess whether the engineering of exosomes significantly changed the
intraluminal nucleic acid profile of the exosomes, samples were prepared and sent
to System Biosciences (SBI) (CA, USA) for their ExoNGSTM deep sequencing
analysis. Sample preparation involved sending SBI the cultured media collected
from transfected cells incubated in Ultraculture + 1% Pen-Strep/Glutamine,
whereupon they performed their own exosome isolation procedure. The results
from this analysis were communicated via the UC Santa Cruz Genome Browser.
Of note, Kalpana Pillai (Scientist II, SBI) lended her expertise in the interpretation
of the results. Statistical analysis of the results was performed with the guidance
of Dr. Maryam Mobed-Miremadi (Sr. Lecturer, Department of Bioengineering,
Santa Clara University) using MATLAB (MathWorks; MA, USA).
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3.

2.9.

Exosomal Liquid Chromatography / Mass Spectroscopy
To determine whether the transfected constructs of interest had truly been
expressed on the surface of the engineered exosomes, samples were again
prepared and sent to SBI for their Proteomics service. The sample preparation
technique for SBI’s ExoNGSTM service was again employed here. The
combination of liquid chromatography and mass spectroscopy allowed for a rapid
and accurate analysis of each sample’s complete protein profile. Results were
communicated via Microsoft Excel and analyzed via MATLAB.

2.10.

Exosome Uptake Assay
A preliminary uptake assay was performed using stained control exosomes to
evaluate how the exosomes interacted with living cells in vitro. The exosomes
were first prepared and isolated from healthy 293T cells as described above.
These isolated control exosomes were then stained using SBI’s ExoGlowTM
exosomal RNA stain in a solution of 100 uM stain to 60 ug exosomes and 300 uL
ExoGlowTM incubation buffer. This mixture was wrapped in tinfoil, as the stain
was sensitive to light, and allowed to incubate briefly before being stored at 4oC
until use. Meanwhile, healthy 293T cells were seeded on a 4-well imaging plate
and allowed to grow to 80% confluency in complete media. When the stain was
added to the cells, the serum helped prevent unbound stain from entering the cells,
thereby reducing the risk of a false positive. After 48H, the uptake assay was
imaged using a confocal microscope.

RESULTS
3.1.

Evaluating 293T Single and Double Transfection Efficiency
3.1.1. Single Transfection
The engineered exosomes created herein had two biological constructs
integrated onto the outer surface of their membranes. To create these
engineered exosomes, the process began by introducing the genetic
instructions for the biological components of interest to healthy 293T cells
via transient transfection. In theory, these cells would digest the genetic
material, synthesize the encoded constructs with their native faculties, and
package these constructs into exosomes via the process of exosome
biogenesis [1,31]. From there, the tVSVG element included in each
construct facilitated the shuttling of the constructs to the surface of the
exosomes for integration. This function of tVSVG has been validated in
prior works [12,24,25,26,27]. The generated constructs were then able to
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be visualized because of the GFP or RFP reporter included in their
sequence.
Importantly, each construct’s ability to be manufactured by human cells
was first validated individually by way of single transient transfection.
The validation process for single transfections included confocal
microscopy fluorescence imaging of the cells at 24H, 48H, and 72H
post-transfection. In Fig. 2b, the confocal microscope was able to capture
with single cell resolution the biodistribution of the translated constructs in
living cells. This technology was also able to provide insights into the
transfection efficiency for single transfections (Fig. 2a). The efficiency
appeared to be above 80% for each construct. However, using a
microscope to gauge transfection efficiency introduces a sampling bias
because the device is able to image only a small portion of the cell
population at a time. Therefore, flow cytometry was employed for a more
global read on transfection efficiency once the experiments moved on to
co-transfections. Nonetheless, these visualizations of single transfections
were deemed to provide sufficient validation for moving forward to
co-transfections.
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Fig. 2: Single transfection images captured by confocal microscopy. (a) A confocal image
was taken at 40X zoom to provide an insight into the transfection efficiency for a single
construct. This figure showed these results for the TN construct, and the RVG and the NCAM
single transfection results reflected similar efficiencies. (b) Zooming into single cell resolution,
the confocal was able to visualize the biodistribution of successfully transfected, transcribed, and
translated constructs. This biodistribution was not expected to exist in the nucleus, nor to be
concentrated at the cell’s membrane. Both of these expectations were validated. TL - transmitted
light microscopy (i.e. contrast image).
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3.1.2.

Cotransfection
The bulk of the scientific contribution in this work came from studying the
surface engineering of exosomes with two medically relevant constructs.
One of the constructs, RVG, was constant across both engineered groups.
This construct has been noted as being able to target bioactive compounds
to the nicotinic acetylcholine receptors (nAChRs) in neurons [5]. The
other construct was either TN or NCAM. Both of these latter constructs
have been indicated as being able to facilitate shuttling across the BBB
[17,18,19,20]. These two experimental groups, along with the control
group, were illustrated below in Fig. 3.
The work for validating the transfection of the cells with two constructs
was analogous to the validation of the single transfections, with the
notable inclusion of flow cytometry. In Fig. 3b, the confocal microscope
provided encouraging results in an image that showed colocalization of the
cotransfected constructs in the RVG/NCAM group. At the same time, the
confocal also illustrated the possibility that the efficiency of
co-transfections may have been lower than that of single transfections.
Namely, high proportions of the cell population were able to translate at
least one of the constructs, but cells that were able to translate both of the
constructs in similar amounts were less common. However, there existed
the possibility that the confocal was not able to pick up every fluorescent
signal, especially because the fluorescent constructs were, in theory, being
shuttled to exosomes, and exosomes are far too small to be imaged with
high resolution on a confocal microscope. This limitation acknowledged,
the confocal images provided sufficient evidence for validating successful
co-transfections of both engineered groups.
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Fig. 3: Confocal images of the cotransfected test groups. The logic for combining RVG with
either TN or NCAM was that either of the latter should be able to help shuttle exosomes across
the BBB, and the RVG moiety should target the engineered exosome to neurons once inside the
parenchyma [5,6,7,17,18,19,20]. Of note, different reporters were used at different stages of the
experiment. For this reason, the reporter has been noted in most cases. Also, Group II was
crossed out here because it was not imaged in this part of the experiment. (a) The three confocal
channels that capture GFP, RFP, and brightfield images were observed for the control cell sample
individually and as an overlaid image. (b) was organized similarly for the RVG/NCAM group. In
contrast to the control images, strong reporter signals were detected in the cotransfected group,
and the two reporters appeared to be co-isolated.

In an effort to remove the sampling bias involved in imaging small subsets
of the cell population at a time, flow cytometry was employed at 48H
post-transfection (Fig.4). The 48H mark was selected for flow cytometry
analysis because cells imaged at this time tended to show the strongest
reporter signal while also maintaining cell viability. Of note, all three
constructs used in the engineered groups analyzed with flow cytometry
had GFP as their reporter, thereby providing valuable, albeit incomplete,
analysis into their co-transfection efficiencies. The flow cytometry data
presented in Fig. 4 indicated a significant shift in the GFP signal in both
engineered samples when compared to the control sample. Numerically,
19

this data indicated with confidence that 41% of the RVG/TN group and
27% of the RVG/NCAM group, from a population perspective, were
transfected successfully. These percentages were retrieved by gating the
portions of the engineered samples in Fig. 4a’s graph that were outside of
the control’s distribution. This data, in conjunction with the confocal
microscopy data, was encouraging enough for the experiment to move
towards exosome isolation and characterization.

Fig. 4: Flow cytometry analysis of cotransfected test groups. (a) Flow cytometry analysis
aims to quantify whether or not there exists a significant shift in the characteristic peaks of
different samples. Focused on the GFP-detecting channel (FITC), this graph compared the
representative whole of each of the three samples, thus providing a more global analysis on the
efficiency of co-transfection than the confocal alone. With the instrument’s software, the flow
cytometer was able to conclude with confidence the minimum co-transfection efficiency for both
of the engineered samples (41% for RVG/TN, 27% for RVG/NCAM). The chart in figure (b)
depicted the magnitudes of difference in mean GFP signal between the control sample and the
two engineered samples.

With the knowledge that the cells were able to translate the instructions
fed to them in both single and co-transfections, we aimed to establish
whether or not the constructs the cells had generated were in fact being
shuttled to exosomes. To begin answering this question, the cells were
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cotransfected with one of the three constructs of interest and one of two
known exosome markers, either CD63 or XPackTM [28,29,30]. As seen in
the images organized in Fig. 5, RVG, TN, and NCAM were each shown to
colocalize with both of these exosome markers. This observation provided
an initial validation that allowed us to continue on with isolating the
engineered exosomes for a more refined exosome characterization.

Fig. 5: Colocalization experiments with known exosome markers CD63 and XPackTM. (a)
The top row of images in this figure, images 1-4, visualized the colocalization of TN with CD63.
The bottom row, images 5-8, depicted the colocalization of TN with XPackTM. In both series of
images, TN was shown to colocalize strongly with both exosome markers. The figures for
visualizing (b) NCAM’s and (c) RVG’s colocalization with these same exosome markers were
organized analogously to part (a) and also showed competent colocalization.

3.2.

Exosome Isolation
3.2.1. NanoDropTM Lite
Following the exosome isolation procedure outlined above, an initial
characterization with a NanoDropTM Lite provided an estimate on the
isolation’s success. This estimate was provided by way of correlating the
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protein concentration reading provided by the NanoDropTM in mg/mL to
the concentration of isolated exosomes. This correlation was based on the
assumption that the only proteins present should have belonged to isolated
exosomes. The average protein concentration detected by the NanoDropTM
for exosome experiments coming from Dr. Lu’s lab has generally landed
between 1-2 mg/mL. The protein concentrations detected for this
experiment were in this range for the control, but were significantly higher
in both the engineered groups, landing in the 3-4 mg/mL range. This
increase in protein concentration may have indicated a corresponding
increase in exosome production following co-transfection, but this
possibility could be validated only through further methods. Therefore,
future work may employ nanoparticle tracking analysis (NTA) in order to
provide a more accurate read on both the concentration and the size
distribution of the isolated exosomes.
3.3.

Exosome Characterization
3.3.1. Confocal Microscopy
In-house characterization of the isolated exosome populations involved
visualizing the three isolated exosome populations—one control and two
engineered populations—under the confocal microscope to determine if
the constructs, by means of their respective reporters, were in fact
detectable in the isolated exosome samples. In Fig. 6, the confocal was
able to detect a strong GFP signal in both of the engineered exosome
populations, but not in the control exosome population. This result was
expected because the RVG and TN constructs here were designed with
GFP reporters. Of note, GFP was known to be an inherently stronger
signal than RFP, and this understanding was incorporated into the analysis.
Furthermore, the confocal detected a strong RFP signal in the
RVG/NCAM population, and this result was expected because the NCAM
construct used in this branch of the experiment was designed with an RFP
reporter. However, the RVG/TN population was not expected to contain a
detectable RFP signal because both the RVG and the TN constructs used
here contained a GFP reporter. This unexpected RFP signal might
reasonably have been explained by an instance of fluorescence overlap,
wherein the GFP signal was inaccurately detected by the confocal’s RFP
channel. This explanation was considered reasonable because the control
channel did not present an RFP signal, the RVG/TN population’s RFP
signal was significantly less than its GFP signal, and this same
population’s RFP signal was also significantly less than the RVG/NCAM
population’s RFP signal.

22

Fig. 6: Confocal images of isolated exosomes. Although unable to be visualized either
individually or all at once due to the limitations of this microscopic technique, these confocal
images were able to allow for a local visualization of isolated exosomes. Of note, the GFP and
RFP channel exposures were doped to be twice as sensitive to detecting reporter signals.

With this characterization step’s results, the constructs were confirmed to
be detected in both of the isolated engineered exosome samples and not in
the isolated control exosome sample. Questions remained regarding
whether the engineering process significantly changed the exosomes’
intraluminal ribonucleic acid (RNA) content, as well as whether the
constructs had been integrated successfully into the engineered exosomes’
membranous surfaces. These two powerful questions were addressed by
third-party deep-sequencing and proteomics services, respectively.
3.3.2.

Next-Generation Sequencing
The end goal of this project had always been rooted in the medical
relevance of the engineered exosome technology. Building from the
exosome’s natural capabilities, the constructs were selected for their
respective therapeutic capacities, and the cell line was selected in order to
be able to make accurate correlations between observed experimental
outcomes and the potential outcomes in a patient. With this application in
mind, considerations had to be made as to whether or not the engineering
process described herein significantly impacted the innate
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biocompatibility of naturally derived exosomes. Answering this question
was the primary focus for enlisting SBI’s ExoNGSTM deep sequencing
service. Through this process, insight into the RNA content contained in
the exosome samples was gathered. Naturally, exosomes have the
characteristic of being biocompatible [1]. However, were the engineering
process to significantly change the RNA profile of an exosome, the
engineered exosome may pose a risk to the health of a potential patient.
For example, were the mRNA transcript of a key regulatory enzyme to be
upregulated by a 4-log increase, the patient may experience an adverse
reaction to the treatment that does not relate to the therapeutic cargo in
question, but rather to the engineering process itself [32]. Understandably,
such situations should be avoided primarily for the sake of the patient’s
safety, and also for the sake of making accurate interpretations of what has
happened in a preclinical or clinical trial setting.
Distinguishably, the engineered samples sent to SBI for deep sequencing
were not engineered with the exact same combinations of constructs as
were used in the two engineered test groups. The deep sequencing samples
included a control of 293T cell-derived exosomes, accompanied by four
engineered exosome samples. Namely, the exosomes in the four deep
sequencing samples were engineered singularly with either a CD9, a
CD63, a CD81, or a VSVG construct. The value of evaluating these
samples was two-fold. First, the engineering process used to modify these
samples was the same process used to modify the two engineered test
group samples. Therefore, these results gave insight into the engineering
process itself. Secondly, VSVG was included as a membrane-targeting
scaffold in all three of the test group constructs (RVG, TN, and NCAM).
Therefore, the comparison here between the control sample and the VSVG
sample was of particular importance (Fig. 8b).
The process of deep sequencing an exosome sample began by preparing
conditioned media from each of these five sample groups—Control, CD9,
CD63, CD81, and VSVG—from which SBI performed its own exosome
isolation procedure. Each exosome population was tested separately, and
every RNA read for each sample was sorted by both quantity and RNA
type. These categorizations allowed for statistical pairwise comparisons
between RNA population means (Fig. 7b), as well as more biological
comparisons between the RNA types recognized in each sample (Fig. 8
and Fig. 9a). Of note, the RNA class of microRNA (miRNA) was subject
to a more in-depth analysis in Fig. 9b than its neighboring classes because
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of the significant biological functionality that miRNAs have been reported
to influence, particularly in cancer [29,33].
Before analyzing this data, importance had to be put on assessing the
quality of the data. According to SBI, this data quality could be affected
most likely by the purity of samples and the corresponding efficacy of the
exosome preparation and isolation processes. In the field of deep
sequencing, this assessment involves categorizing the reads into those that
were able to be mapped—in this case, reads that were able to be mapped
to the human genome—and those that were not mappable. In the ideal
case, every read was able to be mapped. However, SBI advised that a
sample assessed to have more than 70% of its reads mapped could be
considered as providing good quality data. Seeing that many of the
samples were closer to 90% mapped reads, SBI noted that these samples
were of a high quality. Knowing that the data could be considered as high
quality supported the value of its subsequent analysis. Fig. 7a below
provided this quality assessment.
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Fig. 7: Deep sequencing quality, pairwise, and normality analysis. (a) Quality assessment of
deep sequencing data. Quality data in deep sequencing can be defined by how many reads in a
sample were able to be mapped to the reference genome (e.g. human). The higher the percentage
of mapped reads in a sample, the better the data’s quality, and a percentage above 70% indicates
good quality data. Every sample tested was shown to meet this threshold, and the engineered
samples were shown to be above 90%, thus indicating high sample purity. (b) Pairwise
comparison between NGS population means. The mean was indicated for each sample by a
hollow circle in between standard error bars. These error bars indicated the variance associated
with each sample, and the comparison between the sample read count range covered by each
sample’s error bars illustrates how the null hypothesis—that the samples have the same mean as
the control—cannot be rejected at the 95% Confidence Interval (CI). (c-d) QQ plot normality
assessments for Control and VSVG samples, respectively. The normal distribution was indicated
by the red dashed lines, while the sample data were indicated with blue crosses. In a QQ plot, the
more these two lines overlap, the closer the data is to being normally distributed. Visually, these
plots indicated that most of the Control and the VSVG samples’ data followed a normal
distribution until a heavier right tail and a few significant outliers took shape.
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Continuing with the statistical analysis of the deep sequencing results, a
pairwise comparison of each sample’s population mean was performed,
and the results of which were observed in Fig. 7b. The key findings of this
analysis were the fact that because the variance was so great between each
population’s mean, the null hypothesis that the population means were the
same could not be rejected at the 95% CI. As can be seen in the figure, the
means themselves were not necessarily overlapping, but their standard
errors were, thereby protecting the null hypothesis. Certainly, evaluating
more than one sample for each group would provide valuable information
to either support or reject this pairwise comparison. However, being
conscientious of funds spent on more preliminary research, these initial
characterizations were limited to one sample per group. Also worth noting
when analyzing this comparison were the assumptions underlying it. This
pairwise comparison was built from statistics gathered in a one-way
ANOVA (Analysis of Variance) statistical test, and this ANOVA’s
underlying assumptions involved (1) the data being normally distributed,
(2) each datapoint being independent from each other, and (3) the variance
between each sample being equivalent. In an effort to validate the findings
of the pairwise comparison, these assumptions were tested. The variance
of each sample was compared using a Bartlett test, and the normality of
each sample was compared both with a qualitative QQ plot and with a
quantitative Anderson-Darling test. The results of the Bartlett test
indicated that the samples did not have equivalent variances. Furthermore,
each of the Anderson-Darling tests confirmed that none of the samples’
data were normally distributed. However, focusing on the Control and
VSVG samples, the QQ plots presented in Fig. 7c-d illustrated the notion
that these two datasets were mostly normally distributed, but also included
heavy right-sided tails and a few significant outliers that could not be
removed. Therefore, this comparison still provided a valuable layer of
analysis of the deep sequencing samples and supported the efforts of
further analysis.
Additionally, the biological information encoded in the deep sequencing
data was evaluated by comparing the fifteen different RNA types read in
each sample in the clustered histogram presented in Fig. 8a below. First,
on the recommendation of SBI, the read counts were filtered in a way such
that any RNA with a count below 25 reads was removed from the dataset.
This filtering accounted for any potential oversensitivity of the deep
sequencing process, thereby allowing the data to more confidently reflect
each sample’s RNA profile. Next, each sample’s filtered data was split
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into fifteen categories corresponding to each RNA type detected. For each
category in each sample, the relative percentage of that category was
calculated. An example of this calculation involved summing all of the
counts of the control sample’s filtered data to obtain a total control RNA
count, and then dividing the number of counts in the control sample’s
filtered miRNA category by this total control RNA sum to obtain the
relative percentage of the miRNA class in the control sample. In other
words, when looking at the “RS” group in Fig. 8a, this RNA class appears
to make up around 35% of each sample’s total RNA profile. This
weighing of classes by their respective relative percentages removed the
bias associated with each sample having a different number of RNAs that
passed through the filtering step. Generally speaking, the relative
percentage of each RNA type appeared to be conserved across each
sample. This conclusion was conserved in Fig. 8b’s comparison between
the Control and VSVG samples. For reference, were the five samples
tested here to be collected from five different preparations of the same
control cell line, the inherent variability in exosome biology and cargo
may well have resulted in differences between each sample’s RNA profile
[1,21]. In fact, when comparing the top 50 miRNAs detected across the
five samples, a comparison was also made between our control and the
control SBI provided. Both controls were derived from the 293T cell line.
Around 80% of miRNAs were conserved between our control and each of
the four engineered samples, but only 42% were conserved between the
two unmodified controls. Regardless, the observed results in Fig. 8,
although encouraging of the hypothesis that the engineering process did
not significantly change the engineered exosomes’ RNA profiles,
remained limited to only a few samples. Further work remains to be done
to more conclusively test this hypothesis.
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Fig. 8: Categorical analysis of ExoNGSTM data across five samples. This analysis returned 15
categories of RNA—2 coding classes in RS and RSa, and 13 non-coding classes in the
rest—with a wide variety of biological functions. (a) This segment formatted the relative
percentages for each sample’s RNA profile into a clustered histogram for a qualitative pairwise
comparison. (b) Herein, the information from (a) was converted into pie charts to provide a
different qualitative analysis. Part (b) focused on the comparison between the Control and the
VSVG samples’ RNA profiles because this comparison was most relevant to this work. Of note,
some RNA classes were too small to be visualized in these pie charts. A glossary of the RNA
types follows: miR - microRNA (miRNA); oncR - other non-coding RNA; oncRa - oncR
antisense; rfam - unclassifiable RNA recognized in the rfam database; tR - transfer RNA
(tRNA); tRl - tRNA-like; piR - PIWI-interacting RNA (piRNA); rR - ribosomal RNA (rRNA);
lincR - long intergenic non-coding RNA (lincRNA); lincRa - lincRNA antisense; RS - RefSeq
(coding RNA, or messenger RNA [mRNA]); RSa - coding RNA antisense; scaR - small Cajal
body-specific RNA (scaRNA); CDB - CDBox; HAB - HAcaBox.

Zooming in on the biological analysis of the deep sequencing data, the
miRNA class was put under further analysis in Fig. 9 below. This focus on
miRNA was grounded in the significant role this RNA class has been
reported to play in physiological and pathological activity [29,33]. From
this notion of miRNA’s critical role, a hypothesis was made postulating
that this class would comprise a substantial portion of each sample’s RNA
profile. However, Fig. 9b illuminated a different picture. This figure
focused on the miRNA (miR) cluster in Fig. 8a’s histogram. In objection
to this hypothesis, this portion of the histogram indicated that the miRNA
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content of these five samples averaged around two percent of each
sample’s total RNA composition. Potentially, this relatively small
abundance of miRNAs could still be potent in its biological influence. For
instance, perhaps this category’s members can be considered key
regulators, checkpoints in various biological pathways [33]. Were this
description to be accurate, the idea of miRNA as having a powerful impact
on the human body may be maintained. A deep-dive into the biological
functions these miRNAs influenced would be necessary for investigating
this subsequent train of thought, and may well comprise valuable future
research efforts.

Fig. 9: RNA profile analysis focused on the miRNA class. (a) The top 50 most abundant
miRNA members for each exosome sample were organized to be compared with the control.
Accompanied to the right by a legend explaining how to read this heatmap, this table illustrated
how these miRNAs were conserved across the four engineered samples and SBI’s 293T control
sample. The percentage of members conserved with respect to the control was included at the
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bottom of each column. (b) This figure was expanded from Fig. 8a’s clustered histogram, thereby
encouraging comparisons between the miRNA abundance present in each sample.
A second hypothesis regarding the miRNA class was based around the
inquiry of whether or not this category’s most abundant members were
conserved with respect to the control exosome sample. To quantitatively
probe this hypothesis, the table in Fig. 9a was created. This table took the
top 50 miRNAs read in each sample and compared them with respect to
the control. The first observation was that many of the miRNAs were
shared between the control and the four engineered exosome samples,
even though they may have occupied a different position in the ranking.
Of note, there were some miRNAs not conserved in the engineered
samples. Quantitatively, between 80-92% of the control’s miRNA
demographic was conserved in the engineered samples. On the other hand,
surprisingly, the two controls—both unmodified and derived from the
same cell line—had less than half of their top 50 miRNAs overlap. These
insights promoted two takeaways. First, the idea that the variability
inherent in biology can be dramatic was reinforced. Second, at this
experimental stage, a preliminary indication that the process used to
engineer these exosomes may not significantly change their miRNA
profile—and, by ambitious extrapolation, the global RNA profile—was
observed. Were this second takeaway to be validated further and expanded
to the complete RNA profile, this analysis would provide valuable
preclinical insights into the degree of safety that could be reasonably
expected from an engineered exosome therapy. Such insights are critical in
determining the characteristics of clinical trials, such as the number of
patients needed for each treatment arm and the trial’s predicted risk [34]
3.3.3.

Liquid Chromatography / Mass Spectroscopy
Moving forward, the question remained regarding whether or not the
constructs were able to be integrated into the surface of the engineered
exosomes. To address this question, SBI’s Proteomics service was
employed on the three test groups—Control, RVG/TN, and RVG/NCAM.
This service utilized liquid chromatography-mass spectroscopy (LC-MS)
as its protein isolation and detection system. The detection confidence, as
described by the protein false discovery rate (FDR), was set by SBI at
0.01%, indicating a 99.99% confidence when identifying a protein.
Detected proteins were identified as either a member of the human
proteome or a likely contaminant by mapping them against both the
UniProt human reference proteome and the CRAPome contaminant
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database. All three of the test groups were analyzed for their complete
protein profiles, which included surface proteins and cytoplasmic proteins.
Statistical comparisons were made between detected proteins of interest
(POIs)—those proteins encoded by the RVG, TN, and NCAM
constructs—across the samples. The null hypothesis for each of these
comparisons was that the abundances of these POIs were not different for
either of the engineered samples or the control.
RVG was not detected in this LC/MS analysis. An explanation for this
observation might have existed in the fact that RVG cannot be found in
either database used herein for protein fingerprinting. Potentially, the raw
data file could be mapped against a viral proteome database and this POI
may hence be detected. Alternatively, an RVG-targeted ELISA could be
run against the samples. An exosome dye may be included in the ELISA
procedure to deduce whether or not the RVG has been coupled to the
exosome surface.
TN was present in multiple forms. Transferrin (TN), lactotransferrin
(LTF), and serotransferrin (TF) were all present in each sample. The null
hypothesis was that the TN abundance in each of the three samples was
the same. This hypothesis was also held for lactotransferrin and
serotransferrin. Notably, neither of these latter two proteins were
intentionally engineered into the exosomes, and, therefore, changes in
lactotransferrin or serotransferrin levels were not expected. However, an
increase in TN in the RVG/TN group was expected. Notably,
serotransferrin and transferrin have often been considered the same protein
because transferrin’s nature as a blood-plasma glycoprotein generally
lends itself to being serological. Therefore, questions remain as to whether
or not TF was secreted by the exosomes or was successfully integrated
into their surface. Comparing the TF values detected, a 270-fold increase
in the RVG/TN sample with respect to the Control group indicated a
significant upregulation. A 44-fold increase with respect to the
RVG/NCAM sample indicated an unexpected finding. These findings may
or may not validate our expectation if, in fact, these transferrin family
proteins had been integrated into the exosome surface. In comparing LTF
detection values, all of the samples differed by less than 2-fold, an
insignificant difference that matches the expectation. Comparing TN
values resulted in a similarly small difference, with each sample differing
by less than a factor of 2. This comparison was expected to yield the most
significant variation. Therefore, a possible conclusion was to acknowledge
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the notion that although TN and TF were initially considered to be distinct
proteins, perhaps the two proteins were actually the same. Nevertheless, a
more thorough analysis must strive to discern where the TF protein was
analyzed from in the exosome sample to determine whether it was
cytoplasmic, surface, or extracellular in location.
NCAM was detected in both of the engineered samples, but not in the
control sample. Therefore, the null hypothesis adjusted to posit that these
two groups did not have a significant difference in NCAM abundance.
Notably, the proteomics results were scoured for NCAM’s aliases, namely
CD56, MSK39, and NCAM1, without success. Nonetheless, the
RVG/NCAM sample had a 2.5-fold increase in NCAM abundance with
respect to the RVG/TN sample. Acknowledging the limitations of any
conclusion drawn between populations consisting of only one sample a
piece, the tentative conclusion can be made that exosomal transferrin was
upregulated by a larger degree than NCAM. If the BBB-crossing capacity
of the engineered exosomes can be directly correlated to the abundance of
the BBB-crossing protein it has been equipped with—either transferrin or
NCAM—then this enhanced abundance of transferrin may indicate the
RVG/TN group as having a better chance of reaching the brain’s
parenchyma.
Additional questions probed by this proteomics analysis included: (i)
Could this analysis indicate whether or not the exosomes were derived
from healthy cells? (ii) Were there markers whose detection would support
the logic behind using an exosome as a therapeutic delivery vehicle? And
(iii) Did there exist markers that have been indicated as being involved in
neurological diseases? Many of the markers studied herein were presented
in Pellenz’s exosome protein marker table, which draws from numerous
supplementary references [35]. The value of the first question, in
conjunction with the deep sequencing analysis, provided insight into
whether or not the engineering process was harmful to the exosomes or the
cells from which they came. Were the process harmful, there may have
existed implications to the safety of the engineered exosomes or to their
scaled manufacturing. For example, were apoptosis markers to be present
in the engineered exosomes because their parent cells were damaged,
these exosomes could have adverse effects. The second question looked to
probe for the presence of proteins that would naturally help the exosomes
perform as a targeted therapeutic delivery vehicle. The third question was
important because, although the cells these exosomes were derived from
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belonged to a healthy cell-line, the presence of these specific markers
would introduce the risk of pathological development, and also the
possibility for introducing targets for therapeutic intervention, ultimately
indicating exosomes as playing a role in neurology.
The first question was examined by looking for the presence of native
exosome protein markers, such as members of the tetraspanin family; for
protein markers associated with exosome formation; and for apoptosis
markers. Resources that link tetraspanins as exosome markers, as well as
resources that link specific markers with exosome formation and
apoptosis, have been referenced [28,36,37,38,39]. Numerous tetraspanins
were identified in the three samples, including CD63, CD81, CD151,
tetraspanin-3 (TSPAN3), and tetraspanin-6 (TSPAN6). CD63 and CD81
especially have been indicated as exosome markers, thus confirming the
notion that the samples consisted of robust exosomes [28,29]. Regarding
exosome formation markers, programmed cell death 6-interacting protein
was observed in all three samples at a magnitude of 107, and tumor
susceptibility gene 101 protein (TSG101), syntenin-1, and
vacuolar-sorting protein 35 (VPS35) were similarly observed
[36,37,38,39]. For apoptosis markers, 14-3-3 proteins epsilon and
zeta/delta were detected at magnitudes of 107 [40]. Consequently, the
process of encouraging cells to secrete exosomes may have damaging
effects on the exosomes’ parent cells. While, on the one hand, this process
produces a large number of exosomes, on the other hand, this process may
equip exosomes with apoptosis factors that may be harmful in a
prospective trial. Thus, valuable research may involve comparing the
yield, vitality, and safety of different exosome harvest methods.
The second question was probed by searching for proteins responsible for
survivability, antigen presentation, or targeting and adhesion. Proteins
linked to all of these characteristics were detected. Encouraging in vivo
survivability, leukocyte surface antigen CD47 was identified in all three
samples at abundances above 105 [41]. For antigen presentation,
lysosome-associated membrane glycoprotein 1 (LAMP1) was detected in
both of the engineered samples with an abundance above 106 [42]. For
targeting and adhesion, integrin beta-1 was detected in all three samples at
a magnitude above 106 [43]. Together, these findings support the notion of
exosomes as natural targeted delivery vehicles worth researching as
therapeutics.
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The third question was answered when amyloid-beta precursor protein
(APP), disintegrin and metalloproteinase domain-controlling protein 10
(ADAM10), leucine-rich repeat serine/threonine-protein kinase 2
(LRRK2), and VPS35 were detected in all three samples above
abundances of 105 [39,44]. Subsequently, the notion that exosomes may
well play an important role in neurology, both physiologically and
pathologically, was supported. This observation further reinforced the
value of researching therapeutically engineered exosomes in the context of
brain cancer.
3.3.4.

Exosome Uptake Assay
Following these characterizations of isolated exosomes, we were
interested in how they would interact with healthy cells. An exosome
uptake assay of stained control exosomes introduced to healthy 293T cells
served as the first experiment. Exosomes were stained and the assay was
performed according to the methods prescribed above. Fig. 10 presents the
findings of this assay. Encouragingly, the stained control exosomes appear
to have been readily taken up in vitro. Perhaps this uptake was mediated
by the fact that these exosomes were derived from this cell-line and,
therefore, may be readily recognizable.

Fig. 10: Confocal images of control exosome uptake assay. Taken at two different
magnifications, these confocal images provide initial insight into the uptake characteristics of
control exosomes. The exosomes were stained with a green-fluorescing RNA probe prior to
incubation with healthy 293T cells. Serum-containing media in the assay helped prevent false
positives by binding to unbound stain before it could enter into the cells.
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4.

DISCUSSION
The four main challenges facing targeted therapeutic delivery vehicles to the
brain—survivability, BBB-crossing, diseased tissue targeting, and uptake of
vesicle-delivered therapeutic cargo by target cells—must be addressed one by one before
being put together. Thus, preliminary work was ensured to be in place before embarking
on this project. Namely, past research has probed and worked to optimize the surface
engineering of exosomes with medically relevant proteins [12,14]. Additional efforts
have studied the loading of engineered exosomes with therapeutic agents and their
subsequent uptake by target cells [13,16]. Further unpublished work by D. Diebold and
K. Asano has investigated the engineerability of RVG and NCAM individually. Even
more current research has concentrated on enhancing the survivability of exosomes in
vivo by studying the two immune-evading surface proteins CD24 and CD47.
Consequently, the stage had been set to begin bringing together the pieces of this bigger
project. Focusing on crossing the BBB with a TN- or NCAM-mediated “Trojan horse”
approach and targeting neurons thereafter via RVG, this work analyzed how these two
functionalities may be engineered together.
Notably, the three POIs studied herein may not confer the exact characteristics necessary
for a therapeutic delivery vehicle targeted against brain cancer. Namely, RVG targets
nAChRs, receptors found on both healthy and diseased neurons. If RVG-guided brain
cancer therapies were found to be guided to healthy neurons as often as they were to
diseased neurons, the off-target effects could be detrimental. Evidence does exist that
shows how “AChRs were significantly upregulated in regions of [glioblastoma]
infiltration in situ” [45]. This evidence is impactful because glioblastoma is the most
common malignant brain tumor in adults, and upregulation of AChRs in cancerous tissue
may help localize RVG-guided therapies. Still, conclusive evidence about how
RVG-guided cancer therapies are distributed in the brain is invaluable to RVG’s clinical
use.
In working to quantify the co-transfection efficiency for the two engineered test groups,
confocal microscopy and flow cytometry worked together to provide local and global
insights. However, this analysis was incomplete because all three constructs had GFP as a
reporter. Thus, the flow cytometry analysis was not able to discern the details of how the
two constructs in either engineered sample were contributing to the shifted GFP channel
peak. Further insights would require distinct reporters to be used in the engineered groups
(e.g. RVG-GFP/TN-RFP).
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The exosome uptake assay, although providing positive results, was only preliminary.
Similar assays need to be run using stained exosomes from both of the engineered
samples to determine their uptake characteristics. Also, uptake by healthy 293T cells, a
kidney cell-line, does not provide sufficient inference as to how these exosomes would
interact with either the specialized endothelial cells of the BBB or the neurons of the
brain in a brain cancer patient. Uptake assays run separately on endothelial cells and
neuronal cells would provide valuable insights, but a more accurate in vitro brain cancer
model would still be necessary before moving to clinical studies.
Techniques that may build upon this work’s findings include NTA and ELISA. NTA
would improve the understanding of the exosome isolation step by providing data on the
size distribution of the exosome samples. Individual ELISA tests designed to be specific
for RVG, TN, or NCAM would more thoroughly confirm whether or not these POIs were
integrated by their VSVG-scaffolds into the surfaces of the engineered exosomes.
Furthermore, due to low sample size, the conclusions arrived at by confocal imaging and
proteomics analysis should be considered encouraging and, at the same time, subject to
change in light of future work. Namely, the validity of how significantly, as well as how
consistently, the engineering process was able to integrate two distinct constructs into the
surface of the same exosome is yet to be confirmed. The conclusion drawn from the deep
sequencing analysis, that the RNA compositions of the engineered samples were not
significantly different from that of the control, must also be validated further. A greater
sample size is particularly important for exosome studies in medicine because this
biological species is known to be highly heterogeneous, and good medicine requires
reliability [21]. At the least, this work supports the value of continued work in the area of
exosomes engineered in an effort to create targeted therapeutic delivery vehicles for
indications of brain cancer.

5.

CONCLUSION
Although not fine-tuned to preclinical testing efficacy, engineered exosomes have herein
been shown by the validation tools of confocal microscopy and LC-MS proteomics to be
able to be engineered to express therapeutically relevant chimeric proteins. Notably,
whether or not these POIs have been successfully integrated into the engineered
exosome’s surface remains to be validated. In addition to the BBB-crossing and neuron
targeting functions linked to these integrated proteins, the RNA content—specifically, the
miRNA content—was upon deep-sequencing analysis not altered significantly by the
engineering process. Therefore, not only were the exosomes engineered to have enhanced
medically relevant capabilities, but also the likelihood of a health risk introduced by the
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engineering process was not qualitatively significant. While encouraging, the gravity of
these conclusions was limited by the reality that too few samples were tested to be able to
consider this work complete. Ongoing efforts in this project may find value in utilizing
ELISAs to further evaluate engineered exosome surface characterization, studying a more
global RNA profile comparison, performing a deep sequencing analysis of exosomes
engineered with two constructs, employing an NTA for more conclusive exosome
isolation evidence, analyzing uptake assays on target cells types, and increasing the
sample size for all experiments.
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